4-(S)-benzyl-3-[5-(2-methyl-[1,3]dioxolan-2-yl)-pentanoyl]-oxazolidin-2-one | 227938-77-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(S)-benzyl-3-[5-(2-methyl-[1,3]dioxolan-2-yl)-pentanoyl]-oxazolidin-2-one
• 英文别名: (4S)-4-benzyl-3-[5-(2-methyl-1,3-dioxolan-2-yl)pentanoyl]-1,3-oxazolidin-2-one
• CAS: 227938-77-4
• 化学式: C₁₉H₂₅NO₅
• 分子量: 347.411
• InChiKey: KGDBHHCHZQCRFD-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(S)-benzyl-3-[5-(2-methyl-[1,3]dioxolan-2-yl)-pentanoyl]-oxazolidin-2-one 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 三乙酰氧基硼氢化钠 、 对甲苯磺酸 、 臭氧 、 DL-脯氨酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 3.0h， 生成 (3S)-3-{(3R)-2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]pyrrolidin-1-yl}-3-quinolin-3-ylpropanoic acid
  参考文献：
  名称：

  Non-peptide α v β 3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint

  摘要：

  Antagonists of the integrin receptor alpha(nu)beta(3) are expected to have utility in the treatment of osteoporosis through inhibition of bone resorption. A series of potent, chain-shortened, pyrrolidinone-containing alpha(nu)beta(3) receptor antagonists is described. Two sets of diasteromeric pairs of high-affinity antagonists demonstrated marked differences in log P values, which translated into differing dog pharmacokinctic properties. One member of this set was demonstrated to be effective in reducing bone resorption in rats. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.055
• 作为产物：
  描述：

  5-乙酰基戊酸 在 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 4-(S)-benzyl-3-[5-(2-methyl-[1,3]dioxolan-2-yl)-pentanoyl]-oxazolidin-2-one
  参考文献：
  名称：

  Non-peptide α v β 3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint

  摘要：

  Antagonists of the integrin receptor alpha(nu)beta(3) are expected to have utility in the treatment of osteoporosis through inhibition of bone resorption. A series of potent, chain-shortened, pyrrolidinone-containing alpha(nu)beta(3) receptor antagonists is described. Two sets of diasteromeric pairs of high-affinity antagonists demonstrated marked differences in log P values, which translated into differing dog pharmacokinctic properties. One member of this set was demonstrated to be effective in reducing bone resorption in rats. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.055

文献信息

• Integrin receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06268378B1

  公开（公告）日：2001-07-31

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

  本发明涉及化合物及其衍生物、它们的合成以及它们作为维腾联蛋白受体拮抗剂的用途。更具体地说，本发明的化合物是维腾联蛋白受体αvβ3和/或αvβ5的拮抗剂，可用于抑制骨吸收、治疗和预防骨质疏松症，并抑制血管再狭窄、糖尿病视网膜病变、黄斑变性、血管生成、动脉粥样硬化、炎症、病毒性疾病和肿瘤生长。
• US6066648A
  申请人：——

  公开号：US6066648A

  公开（公告）日：2000-05-23
• US6268378B1
  申请人：——

  公开号：US6268378B1

  公开（公告）日：2001-07-31
• Non-peptide α v β 3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint
  作者：James J Perkins、L.T Duong、Carmen Fernandez-Metzler、George D Hartman、Donald B Kimmel、Chih-Tai Leu、Joseph J Lynch、Thomayant Prueksaritanont、Gideon A Rodan、Sevgi B Rodan、Mark E Duggan、Robert S Meissner

  DOI：10.1016/j.bmcl.2003.09.055

  日期：2003.12

  Antagonists of the integrin receptor alpha(nu)beta(3) are expected to have utility in the treatment of osteoporosis through inhibition of bone resorption. A series of potent, chain-shortened, pyrrolidinone-containing alpha(nu)beta(3) receptor antagonists is described. Two sets of diasteromeric pairs of high-affinity antagonists demonstrated marked differences in log P values, which translated into differing dog pharmacokinctic properties. One member of this set was demonstrated to be effective in reducing bone resorption in rats. (C) 2003 Elsevier Ltd. All rights reserved.